Pedro José Vieira Borga Martins Borrego
PhD (2001) in Pharmacy (Microbiology), Universidade de Lisboa
Researcher, iMed.ULisboa, FF/ULisboaInvited Assistant Professor, Instituto Superior de Ciências Sociais e Políticas (ISCSP), Universidade de Lisboa
Researcher, Centro de Administração e Políticas Públicas (CAPP), ISCSP
Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
Pedro Borrego has been studying the mechanisms of HIV replication, the dynamics of the humoral immune response in HIV infection, and producing new tools, drugs and vaccines strategies for the treatment and prevention of HIV infection. He is also deeply involved on developing gene therapy for HIV cure. He has solid know-how in data analysis, with work published in the biomedical and socio-economic domains.
Borrego P, Gonçalves MF, Gomes P, Araújo L, Moranguinho I, Figueiredo IB, Barahona I, Rocha J, Mendonça C, Cruz MC, Barreto J, Taveira N. Assessment of the Cavidi ExaVir™ Load assay for monitoring plasma viral load in HIV-2 infected patients. J Clin Microbiol. 2017 May 17. pii: JCM.00235-17.
Xiong S*, Borrego P*, Ding X*, Zhu Y, Martins A, Chong H, Taveira N, He Y. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activities against HIV-1, HIV-2 and Simian Immunodeficiency Virus. J Virol. 2017 Jan;91(1):e01839-16 (*these authors contributed equally to this work)
Döring M, Borrego P, Büch J, Martins A, Friedrich G, Camacho RJ, Eberle J, Kaiser R, Lengauer T, Taveira N, Pfeifer N. A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support. Retrovirology. 2016 Dec 20;13(1):85.
Borrego P, Calado R, Marcelino JM, Pereira P, Quinta A, Barroso H, Taveira N. An ancestral HIV-2/SIV peptide with potent HIV-1 and HIV-2 fusion inhibitor activity. AIDS. 2013 April 24; 27(7):1081-90.
Borrego P, Calado R, Marcelino JM, Bártolo I, Rocha C, Cavaco-Silva P, Doroana M, Antunes F, Maltez F, Caixas U, Barroso H, Taveira N. Baseline susceptibility of primary Human Immunodeficiency Virus Type 2 to entry inhibitors. Antivir Ther. 2012;17(3):565-70.